Aralez Pharmaceuticals Announces Issuance Of Additional U.S. Patent For Yosprala

Thursday, January 12, 2017

Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company, announced that the United States Patent and Trademark Office (USPTO) has issued a patent entitled "Compositions and Methods for Delivery of Omeprazole Plus Acetylsalicylic Acid" that covers Yosprala™ (aspirin and omeprazole), the only prescription fixed-dose combination of an anti-platelet agent, aspirin, and the proton pump inhibitor, omeprazole, in the U.S.

The USPTO issued U.S. Patent number 9,539,214 on January 10, 2017, which will expire in late 2032 with possible patent term adjustment into early 2033. Aralez plans to list this patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the Orange Book.  Once listed there will be a total of four patents in the Orange Book for Yosprala.

TOP